C.A.S. 7.11.02

09/831,859

=> d ibib abs hitstr 1-8

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:851123 CAPLUS
DOCUMENT NUMBER: 136:5985
TITLE: Preparation of tricyclic pyrazole derivatives as tyrosine kinase inhibitors for treatment of angiogenesis-related diseases
INVENTOR(S): Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.; Wilkins, David J.; Arnold, Lee D.; Hockley, Michael; Ericsson, Anna M.; Iwasaki, Nobuhiko; Ogawa, Nobuo
PATENT ASSIGNEE(S): Knoll G.m.b.H., Germany
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087846	A2	20011122	WO 2001-US16153	20010517
WO 2001087846	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-573366 A1 20000517
OTHER SOURCE(S): MARPAT 136:5985
GI



I

AB Title compds. I [m = 1-10; X = (CH2)n, CO, O, C:NOR10, NR11, (CH2)n, S, SO, or SO2; n = 1-3; R10 = alkyl; R11 = (un)substituted alkyl or Ph; B = (cyclo)alkyl, aryl, pyridyl, thienyl, furyl, or pyrrolyl; R1 = H, halo, OH, NO2, CN, hydroxyamidino, CH2NH2, formamidomethyl, (un)substituted alkenyl(oxy), alkynyl, or YW; Y = absent or alkyl, alkoxy, O, S, or CO; W = H, OH, (un)substituted Ph, alkoxy, or amino; ring A is optionally substituted with halo, OH, NO2, CN, or (un)substituted alkyl, alkoxy, PhO, carboxy, carbamoyl, amino, amido, aralkyl, alkenyl, or alkynyl; with provisos; and racemic mixts., racemic diastereomeric mixts., tautomers, optical isomers, and pharmaceutically acceptable salts thereof] were prepd. as protein kinase inhibitors, esp. tyrosine kinase inhibitors. Thus, indan-1-one hydrazone (prepn. given) in THF at 0.degree. was treated with BuLi and then with Me 3,4,5-trimethoxybenzoate to give 3-(3,4,5-trimethoxyphenyl)-1,4-dihydroindeno[1,2-c]pyrazole. Example compds. significantly inhibited KDR kinase at concns. of .ltoreq. 50

.mu.M.

IT **268563-38-8P**, 3-[2-(2H-1,2,3,4-Tetraazol-5-yl)-4-pyridyl]-4,5-dihydro-2H-benzo[g]indazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic pyrazole derivs. as tyrosine kinase inhibitors for treatment of angiogenesis-related diseases)

RN 268563-38-8 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-[2-(1H-tetrazol-5-yl)-4-pyridinyl]- (9CI) (CA INDEX NAME)



IT **268564-02-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of tricyclic pyrazole derivs. as tyrosine kinase inhibitors for treatment of angiogenesis-related diseases)

RN 268564-02-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-(4,5-dihydro-2H-benz[g]indazol-3-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:335390 CAPLUS
DOCUMENT NUMBER: 132:347566
TITLE: Preparation of tricyclic pyrazole derivatives as protein kinase inhibitors.
INVENTOR(S): Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.; Wilkins, David J.; Hockley, Michael; Arnold, Lee D.; Ericsson, Anna M.
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000027822	A2	20000518	WO 1999-US26105 19991104
WO 2000027822	A3	20000810	
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 9915132	A	20010807	BR 1999-15132 19991104
EP 1127051	A2	20010829	EP 1999-962700 19991104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
NO 2001002219	A	20010613	NO 2001-2219 20010504
PRIORITY APPLN. INFO.:			US 1998-107467P P 19981106
			WO 1999-US26105 W 19991104

OTHER SOURCE(S): MARPAT 132:347566

GI



I

AB A method of inhibiting protein kinase activity comprises administration of title compds. [I; X = substituted methylene, CO, O, C:NOR7, NR8, (CH2)n, S, SO, SO2; n = 1-3; R1 = H; R2 = (substituted) aryl, pyridyl, thienyl, furyl, pyrrolyl; R3-R6 = H, OH, halo, CO2H, alkoxycarbonyl, (substituted) alkyl, alkoxy, PhO, etc.; R7 = H, alkyl; with provisos]. Thus, indan-1-one hydrazone (prepn. given) in THF at 0.degree. was treated with BuLi and then with Me 3,4,5-trimethoxybenzoate to give 3-(3,4,5-trimethoxyphenyl)-1,4-dihydroindeno[1,2-c]pyrazole.

IT **268563-38-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic pyrazole derivs. as protein kinase inhibitors)

RN 268563-38-8 CAPLUS

CN 2H-Benz[g]indazole, 4,5-dihydro-3-[2-(1H-tetrazol-5-yl)-4-pyridinyl]- (9CI) (CA INDEX NAME)



IT **268564-02-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of tricyclic pyrazole derivs. as protein kinase inhibitors)
RN 268564-02-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-(4,5-dihydro-2H-benz[g]indazol-3-yl)- (9CI) (CA INDEX NAME)



Inventors

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:335255 CAPLUS
DOCUMENT NUMBER: 132:343312
TITLE: Inhibition of the formation of vascular hyperpermeability using inhibitors of KDR tyrosine kinase
INVENTOR(S): Arnold, Lee D.; Bousquet, Peter F.
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027414	A2	20000518	WO 1999-US25903	19991103
WO 2000027414	A3	20000908		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915139	A	20010807	BR 1999-15139	19991103
EP 1126842	A2	20010829	EP 1999-962685	19991103

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

NO 2001002218 A 20010618

PRIORITY APPLN. INFO.: NO 2001-2218 20010504
US 1998-107462P P 19981106
WO 1999-US25903 W 19991103

AB Vascular hyperpermeability in individuals is a prelude to a no. of physiol. events that are often deleterious. Among these events is the formation of edema, diapedesis, aberrant trans-endothelial exchange, extravasation, exudation and effusion, matrix deposition (often with abnormal stromal proliferation) and vascular hypotension. Vascular hyperpermeability and the subsequent events can be inhibited by the administration of a compd. that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. Preferred administered compds. selectively inhibit the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGF tyrosine kinase receptor.

IT **80997-85-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KDR tyrosine kinase inhibitors for inhibition of formation of vascular hyperpermeability)

RN 80997-85-9 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 52837-55-5
CMF C16 H13 N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:145044 CAPLUS
DOCUMENT NUMBER: 132:204079
TITLE: sequence and therapeutic applications for Tpl-2/cot kinase in relation to modulation of inflammatory response
INVENTOR(S): Allen, Hamish John; Dixon, Richard Woodward; Kamens,

09/831,859

Joanne Sara; Wickramasinghe, Dineli; Xu, Yajun;
Belich, Monica Polidoro; Johnston, Leland Herries;
Ley, Steven Charles; Salmeron, Andres

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, USA; Medical Research Council
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011191	A2	20000302	WO 1999-US18543	19990813
WO 2000011191	A3	20000608		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9955633	A1	20000314	AU 1999-55633	19990813
BR 9913070	A	20010508	BR 1999-13070	19990813
EP 1105501	A2	20010613	EP 1999-942203	19990813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001000786	A	20010417	NO 2001-786	20010216

PRIORITY APPLN. INFO.: GB 1998-17930 A 19980818
GB 1998-27712 A 19981216
WO 1999-US18543 W 19990813

AB It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF.kappa..beta., and thus as a modulator of inflammatory responses in which p105 is involved, and as a target for the development of compds. capable of influencing NF<<kapB activation. Screening assays for identifying a lead compd. for phosphorylation of the substrate MEK, p105, I.kappa.B-.alpha., I.kappa.B-.beta., MEK-1, SEK-1, NF.kappa.B. Screening assays to identify compds. that bind to the TPL-2 mol. and directly or indirectly modulate the activity of p105 are further described. These are evaluated in a cell-based assay system. Methods for identifying a lead compd. for a pharmaceutical comprising incubating a compd. to be tested with a TPL-2 mol. and tumor necrosis factor (TNF), under conditions in which, but for the presence of the compd. to be tested, the interaction of TNF and TPL-2 induces a measurable chem. or biol. effect is described. Here a reporter gene in operable linkage with a transcriptional regulatory sequence sensitive to intracellular signals transduced by TPL-2 or NF.kappa.B is included within this assay. This transcription regulatory sequence is responsive to TNF and is further explored with measuring levels of apoptosis and/or cell proliferation and/or an immune response within a cell. The test compd. is selected from a group consisting of protein based, carbohydrate based, lipid based, nucleic acid based, natural org. based, synthetically derived org. based, and antibody based compds. Treatment of a condition assocd. with NF.kappa.B induction or repression is also described. These conditions include rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, insulin-dependent diabetes mellitus, sepsis, psoriasis, misregulated TNF expression, immune system disorder, and graft rejection.

The detn. of the effect of a test compd. on an indicator of signal transduction by the TPL-2 polypeptide is described. Lastly, antibodies are also described which are specific for TPL-2.

IT **80997-85-9**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(test compd. comprising; sequence and therapeutic applications for Tpl-2/cot kinase in relation to modulation of inflammatory response)

RN 80997-85-9 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 52837-55-5
CMF C16 H13 N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:333008 CAPLUS
DOCUMENT NUMBER: 125:127644
TITLE: Method for obtaining improved image contrast in migration imaging members
INVENTOR(S): Limburg, William W.; Mammino, Joseph; Liebermann, George; Griffiths, Clifford H.; Shahin, Michael M.; Malhotra, Shadi L.; Chen, Liqin; Perron, Marie-Eve
PATENT ASSIGNEE(S): Xerox Corp., USA
SOURCE: U.S., 147 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5514505	A	19960507	US 1995-441360	19950515
CA 2169980	AA	19961116	CA 1996-2169980	19960221

JP 08314240	A2	19961129	JP 1996-113456	19960508
EP 743573	A2	19961120	EP 1996-303359	19960514
EP 743573	A3	19970305		
EP 743573	B1	20000906		

R: DE, FR, GB

PRIORITY APPLN. INFO.: US 1995-441360 A 19950515

OTHER SOURCE(S): MARPAT 125:127644

AB Disclosed is a process which comprises (a) providing a migration imaging member comprising (1) a substrate and (2) a softenable layer comprising a softenable material and a photosensitive migration marking material present in the softenable layer as a monolayer of particles situated at or near the surface of the softenable layer spaced from the substrate, (b) uniformly charging the imaging member, (c) imagewise exposing the charged imaging member to activating radiation at a wavelength to which the migration marking material is sensitive, (d) causing the softenable material to soften and enabling a first portion of the migration marking material to migrate through the softenable material toward the substrate in an imagewise pattern while a second portion of the migration marking material remains substantially unmigrated within the softenable layer, and (e) contacting the second portion of the migration marking material with a transparentizing agent which transparentizes the migration marking material.

IT **80997-85-9**
RL: DEV (Device component use); TEM (Technical or engineered material use); USES (Uses)
(transparentizing agent for electrophotog. migration imaging members)

RN 80997-85-9 CAPLUS

CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 52837-55-5
CMF C16 H13 N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1975:57687 CAPLUS

DOCUMENT NUMBER: 82:57687

09/831,859

TITLE: Substituted indeno, naphtho, and cyclohepta pyrazoles
INVENTOR(S): Coombs, Robert V.; Houlihan, William J.
PATENT ASSIGNEE(S): Sandoz-Wander, Inc.
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3843665	A	19741022	US 1973-350141	19730411

GI For diagram(s), see printed CA Issue.

AB Hypotensive, contraceptive, and abortifacient (no data) pyrazoles I (R = 2-, 3-, 4-pyridyl, 2-thienyl, 2-furyl, 2-pyrrolyl, Ph, substituted phenyl; R1 = H, Cl, Me, OMe, CF3; R2 = H, OMe; R1R2 = OCH2O; n = 1,2,3) were prepd. by treating the indanone, tetralone, or benzosuberone with RCHO and cyclizing II with p-MeC6H4-SO2NHNH2.

IT **52837-55-5P 52837-75-9P 52837-76-0P**
52837-77-1P 52837-78-2P 54752-21-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 52837-55-5 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-75-9 CAPLUS
CN 2H-Benz[g]indazole, 7-chloro-4,5-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-76-0 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-7-methyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-77-1 CAPLUS

CN 2H-Benz[g]indazole, 4,5-dihydro-7-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-78-2 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-7,8-dimethoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54752-21-5 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1975:43412 CAPLUS
DOCUMENT NUMBER: 82:43412
TITLE: Substituted naphthopyrazoles
INVENTOR(S): Habeck, Dietmar A.; Houlihan, William J.
PATENT ASSIGNEE(S): Sandoz-Wander, Inc.
SOURCE: U.S., 5 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3842088	A	19741015	US 1973-328402	19730131
US 3957816	A	19760518	US 1974-483626	19740627

PRIORITY APPLN. INFO.: US 1973-328402 19730131

GI For diagram(s), see printed CA Issue.

AB The naphthopyrazole I was prepd. by adding 4-pyridinecarboxaldehyde to 2-bromo-4-methyl-.alpha.-tetralone and cyclizing the spironaphthaleneoxirane II with N2H4. I inhibited fertility at 100 mg

s.c. twice a day.

IT **54286-45-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and fertility inhibiting activity of)

RN 54286-45-2 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-5-methyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1974:425661 CAPLUS
DOCUMENT NUMBER: 81:25661
TITLE: Benzocyclohepta[1,2-c]pyrazoles, indeno[1,2-c]pyrazoles, and naphtho[1,2-c]pyrazoles
INVENTOR(S): Habeck, Dietmar A.; Houlihan, William J.
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 22 pp. Addn. to Ger. Offen. 2,249,644 (CA 79;18707b).
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2317716	A1	19740502	DE 1973-2317716	19730409
NL 7304722	A	19740502	NL 1973-4722	19730405
DD 105225	W	19740412	DD 1973-169993	19730406
BE 797964	A4	19731009	BE 1973-129814	19730409
BE 806671	A4	19740429	BE 1973-137196	19731029
PRIORITY APPLN. INFO.:			US 1972-302595	19721031
			BE 1972-789948	19721011
			US 1973-341392	19730315

GI For diagram(s), see printed CA Issue.
AB Addn. to Ger. Offen. 2,249,644 (CA 79: 18707b). About 40 pyrazoles (I, n = 1, 2, or 3; R = e.g. 2-, 3-, or 4-pyridyl, 2-pyrrolyl, 2-furyl, 2-thienyl, C6H4OMe-4, C6H4CF3-3, C6H3-(OMe)2-3,4, or C6H4Cl-4; R1 = H, Cl, Me, or MeO; R2 = H or MeO; or R1R2 = OCH2O) and their hydrochlorides, useful as antihypertensives or fertility inhibitors, were prepd. by cyclization of the hydrazones II in MeONa and diglyme or in NaOH and hexane.

IT **52837-55-5P 52837-56-6P 52837-75-9P**
52837-76-0P 52837-77-1P 52837-78-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 52837-55-5 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-56-6 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 52837-75-9 CAPLUS
CN 2H-Benz[g]indazole, 7-chloro-4,5-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-76-0 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-7-methyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-77-1 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-7-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 52837-78-2 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-7,8-dimethoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:03:02 ON 11 JUL 2002)

FILE 'REGISTRY' ENTERED AT 17:03:25 ON 11 JUL 2002
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 11 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:04:07 ON 11 JUL 2002
L4 8 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s kdr
L5 1346 KDR

=>

09/831,859

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	37.53	178.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.96	-4.96

STN INTERNATIONAL LOGOFF AT 17:05:35 ON 11 JUL 2002

CA-5- 7-12-02

=> d ibib abs hitstr 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:335255 CAPLUS
DOCUMENT NUMBER: 132:343312
TITLE: Inhibition of the formation of vascular hyperpermeability using inhibitors of KDR tyrosine kinase
INVENTOR(S): Arnold, Lee D.; Bousquet, Peter F.
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027414	A2	20000518	WO 1999-US25903	19991103
WO 2000027414	A3	20000908		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915139	A	20010807	BR 1999-15139	19991103
EP 1126842	A2	20010829	EP 1999-962685	19991103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001002218	A	20010618	NO 2001-2218	20010504

PRIORITY APPLN. INFO.: US 1998-107462P P 19981106
WO 1999-US25903 W 19991103

AB Vascular hyperpermeability in individuals is a prelude to a no. of physiol. events that are often deleterious. Among these events is the formation of edema, diapedesis, aberrant trans-endothelial exchange, extravasation, exudation and effusion, matrix deposition (often with abnormal stromal proliferation) and vascular hypotension. Vascular hyperpermeability and the subsequent events can be inhibited by the administration of a compd. that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. Preferred administered compds. selectively inhibit the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGF tyrosine kinase receptor.

IT **80997-85-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KDR tyrosine kinase inhibitors for inhibition of formation of vascular hyperpermeability)

RN 80997-85-9 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 52837-55-5

CMF C16 H13 N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:145044 CAPLUS
DOCUMENT NUMBER: 132:204079
TITLE: sequence and therapeutic applications for Tpl-2/cot kinase in relation to modulation of inflammatory response
INVENTOR(S): Allen, Hamish John; Dixon, Richard Woodward; Kamens, Joanne Sara; Wickramasinghe, Dineli; Xu, Yajun; Belich, Monica Polidoro; Johnston, Leland Herries; Ley, Steven Charles; Salmeron, Andres
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, USA; Medical Research Council
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011191	A2	20000302	WO 1999-US18543	19990813
WO 2000011191	A3	20000608		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9955633	A1	20000314	AU 1999-55633	19990813
BR 9913070	A	20010508	BR 1999-13070	19990813
EP 1105501	A2	20010613	EP 1999-942203	19990813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

NO 2001000786 A 20010417 NO 2001-786 20010216
PRIORITY APPLN. INFO.: GB 1998-17930 A 19980818
GB 1998-27712 A 19981216
WO 1999-US18543 W 19990813

AB It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF.kappa..beta., and thus as a modulator of inflammatory responses in which p105 is involved, and as a target for the development of compds. capable of influencing NF<<kapB activation. Screening assays for identifying a lead compd. for phosphorylation of the substrate MEK, p105, I.kappa.B-.alpha., I.kappa.B-.beta., MEK-1, SEK-1, NF.kappa.B. Screening assays to identify compds. that bind to the TPL-2 mol. and directly or indirectly modulate the activity of p105 are further described. These are evaluated in a cell-based assay system. Methods for identifying a lead compd. for a pharmaceutical comprising incubating a compd. to be tested with a TPL-2 mol. and tumor necrosis factor (TNF), under conditions in which, but for the presence of the compd. to be tested, the interaction of TNF and TPL-2 induces a measurable chem. or biol. effect is described. Here a reporter gene in operable linkage with a transcriptional regulatory sequence sensitive to intracellular signals transduced by TPL-2 or NF.kappa.B is included within this assay. This transcription regulatory sequence is responsive to TNF and is further explored with measuring levels of apoptosis and/or cell proliferation and/or an immune response within a cell. The test compd. is selected from a group consisting of protein based, carbohydrate based, lipid based, nucleic acid based, natural org. based, synthetically derived org. based, and antibody based compds. Treatment of a condition assocd. with NF.kappa.B induction or repression is also described. These conditions include rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, insulin-dependent diabetes mellitus, sepsis, psoriasis, misregulated TNF expression, immune system disorder, and graft rejection. The detn. of the effect of a test compd. on an indicator of signal transduction by the TPL-2 polypeptide is described. Lastly, antibodies are also described which are specific for TPL-2.

IT **80997-85-9**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(test compd. comprising; sequence and therapeutic applications for Tpl-2/cot kinase in relation to modulation of inflammatory response)

RN 80997-85-9 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 52837-55-5
CMF C16 H13 N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:333008 CAPLUS
DOCUMENT NUMBER: 125:127644
TITLE: Method for obtaining improved image contrast in migration imaging members
INVENTOR(S): Limburg, William W.; Mammino, Joseph; Liebermann, George; Griffiths, Clifford H.; Shahin, Michael M.; Malhotra, Shadi L.; Chen, Liqin; Perron, Marie-Eve
PATENT ASSIGNEE(S): Xerox Corp., USA
SOURCE: U.S., 147 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5514505	A	19960507	US 1995-441360	19950515
CA 2169980	AA	19961116	CA 1996-2169980	19960221
JP 08314240	A2	19961129	JP 1996-113456	19960508
EP 743573	A2	19961120	EP 1996-303359	19960514
EP 743573	A3	19970305		
EP 743573	B1	20000906		

R: DE, FR, GB

PRIORITY APPLN. INFO.: US 1995-441360 A 19950515
OTHER SOURCE(S): MARPAT 125:127644

AB Disclosed is a process which comprises (a) providing a migration imaging member comprising (1) a substrate and (2) a softenable layer comprising a softenable material and a photosensitive migration marking material present in the softenable layer as a monolayer of particles situated at or near the surface of the softenable layer spaced from the substrate, (b) uniformly charging the imaging member, (c) imagewise exposing the charged imaging member to activating radiation at a wavelength to which the migration marking material is sensitive, (d) causing the softenable material to soften and enabling a first portion of the migration marking material to migrate through the softenable material toward the substrate in an imagewise pattern while a second portion of the migration marking material remains substantially unmigrated within the softenable layer, and (e) contacting the second portion of the migration marking material with a transparentizing agent which transparentizes the migration marking material.

IT **80997-85-9**
RL: DEV (Device component use); TEM (Technical or engineered material use); USES (Uses)
(transparentizing agent for electrophotog. migration imaging members)

RN 80997-85-9 CAPLUS
CN 2H-Benz[g]indazole, 4,5-dihydro-3-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 52837-55-5
CMF C16 H13 N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



```
=> s l2
L4            2 L2

=> s l3 or l4
L5            5 L3 OR L4

=> s vascular hyperpermeability?
         103127 VASCULAR
            319 HYPERPERMEABILITY?
L6           87 VASCULAR HYPERPERMEABILITY?
                (VASCULAR(W)HYPERPERMEABILITY?)

=> s l5 and l6
L7            1 L5 AND L6

=> d

L7   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
AN   2000:335255  CAPLUS
DN   132:343312
TI   Inhibition of the formation of vascular
     hyperpermeability using inhibitors of KDR tyrosine kinase
IN   Arnold, Lee D.; Bousquet, Peter F.
PA   BASF Aktiengesellschaft, Germany
SO   PCT Int. Appl., 48 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND  DATE          APPLICATION NO.  DATE
     ----------          ----  --------      ---------------  --------
```

```
PI   WO 2000027414     A2   20000518        WO 1999-US25903  19991103
     WO 2000027414     A3   20000908
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     BR 9915139        A    20010807        BR 1999-15139    19991103
     EP 1126842        A2   20010829        EP 1999-962685   19991103
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     NO 2001002218     A    20010618        NO 2001-2218     20010504
PRAI US 1998-107462P   P    19981106
     WO 1999-US25903   W    19991103


=> s kdr tyrosine kinase?
         1346 KDR
       115896 TYROSINE
       181472 KINASE?
L8          22 KDR TYROSINE KINASE?
               (KDR(W)TYROSINE(W)KINASE?)

=> s l5 and l8
L9           1 L5 AND L8

=> d

L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
AN   2000:335255  CAPLUS
DN   132:343312
TI   Inhibition of the formation of vascular hyperpermeability using inhibitors
     of KDR tyrosine kinase
IN   Arnold, Lee D.; Bousquet, Peter F.
PA   BASF Aktiengesellschaft, Germany
SO   PCT Int. Appl., 48 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2000027414     A2   20000518        WO 1999-US25903  19991103
     WO 2000027414     A3   20000908
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     BR 9915139        A    20010807        BR 1999-15139    19991103
     EP 1126842        A2   20010829        EP 1999-962685   19991103
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
```

```
     NO 2001002218     A    20010618       NO 2001-2218     20010504
PRAI US 1998-107462P   P    19981106
     WO 1999-US25903   W    19991103


=> d his

     (FILE 'HOME' ENTERED AT 10:55:32 ON 12 JUL 2002)

     FILE 'REGISTRY' ENTERED AT 10:56:55 ON 12 JUL 2002
L1             1 S 80997-85-9/RN
L2             1 S 52837-55-5/RN

     FILE 'CAPLUS' ENTERED AT 10:57:57 ON 12 JUL 2002
L3             3 S L1
L4             2 S L2
L5             5 S L3 OR L4
L6            87 S VASCULAR HYPERPERMEABILITY?
L7             1 S L5 AND L6
L8            22 S KDR TYROSINE KINASE?
L9             1 S L5 AND L8

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                   25.20       29.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                   -1.86       -1.86

STN INTERNATIONAL LOGOFF AT 11:00:45 ON 12 JUL 2002
```